Latest Intellectual Property News

Cleo Diagnostics (ASX:COV) posted a 48% jump in annual loss to $5.9 million amid key progress in its ovarian cancer diagnostic test, including completion of a pivotal US trial and preparations for FDA 510(k) submission.

Etherstack posted a record $8.5 million in revenue for the first half of 2026, driven by strong project and support income, but statutory profit fell 67% due to front-loaded costs and higher expenses.

PlaySide Studios reversed a prior-year loss with a 13% revenue increase to $54.9 million and a 144% jump in net profit to $5.4 million, driven by strong Original IP sales and a strategic cost restructure.

BLIS Technologies has kicked off FY27 with a 42% revenue increase and a return to EBITDA profitability, driven by strong B2B growth in Asia Pacific and China.

Yowie Group's revenue declined in the first half of 2026 as it navigated supply chain shifts and cautious retail demand, but the company secured a significant Australian licensing deal and ended costly legacy litigation.

Artrya Limited marked its first full year of US commercial operations with a $25.18 million loss, driven by regulatory clearances, customer contracts, and an $80 million capital raise.

Mount Ridley Mines has lodged a provisional patent for its SelectroTM hydrometallurgical leach technology, demonstrating superior recoveries of rare earths, scandium, and gallium compared to conventional methods. The company is advancing testwork and commercial discussions to capitalise on the innovation.

ION Video has appointed two seasoned executives to its board and elevated Anthony Baker to Managing Director as it sharpens focus on scaling its patented video technology. Founder Finbar O’Hanlon steps back from the board to concentrate on innovation and expanding the company’s IP portfolio.

Critical Resources has bolstered its Mavis Lake lithium project by staking new claims at the Red Hat gold target in Ontario, spotlighting a historical high-grade gold intercept that sharpens exploration focus.

CSL Limited’s FY2026 results reveal modest revenue growth offset by a multibillion-dollar statutory loss driven by restructuring and impairments, alongside a maintained dividend and a strategic focus on sustainable growth.

Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.

Synertec Corporation Limited (ASX:SOP) reported a 19% revenue increase in FY26 alongside its first net operating cash inflow since FY19. The company raised approximately A$6 million through an institutional placement to support working capital and growth initiatives while reaffirming FY27 revenue guidance.